Table 1.
Activity of different antimicrobial agents against most common Enterobacterales species collected in Spain in the SMART study (2016-2018)
| Microorganisms | Percentage of susceptible (S+I)a isolates | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMC (≤8/4) | PTZ (≤16/4) | CTX (≤2) | CAZ (≤4) | FEP (≤4) | ATM (≤4) | CTZ (≤2/4) | CZA (≤8/4) | IMP (≤4) | MEM (≤8) | ETP (≤0.5) | CIP (≤0.5) | LVX (≤1) | AMK (≤8) | COL (≤2) | |
| Escherichia coli | 79.4 | 92.6 | 89.9 | 91.4 | 92.7 | 90.3 | 99.2 | 100.0 | 100.0 | 100.0 | 99.2 | 67.7 | 68.5 | 98.4 | 99.5 |
| Klebsiella pneumoniae | 66.5 | 72.7 | 67.6 | 71.1 | 71.9 | 71.6 | 83.7 | 100.0 | 97.1 | 97.6 | 85.6 | 65.0 | 70.2 | 99.0 | 94.9 |
| Klebsiella oxytoca | 83.0 | 89.4 | 97.7 | 97.2 | 97.8 | 91.1 | 97.2 | 97.8 | 99.4 | 99.4 | 98.3 | 95.5 | 96.1 | 100.0 | 100.0 |
| Proteus mirabilis | 85.5 | 99.5 | 96.6 | 99.1 | 100.0 | 100.0 | 99.1 | 100.0 | 98.6 | 100.0 | 100.0 | 59.2 | 64.2 | 99.1 | --b |
| Enterobacter cloacae | --b | 78.8 | 70.8 | 75.5 | 89.2 | 78.4 | 81.3 | 95.7 | 97.5 | 97.9 | 85.1 | 86.3 | 87.1 | 100.0 | 90.9 |
| Citrobacter freundii | --b | 77.9 | 66.1 | 67.6 | 97.1 | 73.5 | 79.4 | 100.0 | 97.1 | 97.1 | 97.1 | 92.6 | 91.2 | 100.0 | 100.0 |
| Morganella morganii | --b | 98.9 | 83.1 | 86.8 | 97.8 | 96.7 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 63.7 | 75.8 | 100.0 | --b |
| Serratia marcescens | --b | 95.9 | 92.1 | 98.8 | 98.8 | 98.8 | 97.6 | 97.7 | 95.9 | 99.4 | 97.1 | 91.8 | 93.5 | 98.8 | --b |
a
S = susceptible, standard dose, I = susceptible, increased exposure, EUCAST criteria except AMC in which CLSI criteria were considered; bThis species is considered intrinsically resistant to this antimicrobial; AMC: amoxicillin-clavulanic acid, PTZ: piperacillin-tazobactam, CTX: cefotaxime, CAZ: ceftazidime, FEP: cefepime, ATM: aztreonam, CTZ: ceftolozane-tazobactam, CZA: ceftazidime-avibactam, IMP: imipenem, MEM: meropenem, ETP: ertapenem, CIP: ciprofloxacin, LVX: levofloxacin, AMK: amikacin, COL: colistin